Interstitial lung abnormalities have been associated with lower 6-minute walk distance, diffusion capacity for carbon monoxide, and total lung capacity. However, to our knowledge, an association with mortality has not been previously investigated.
To investigate whether interstitial lung abnormalities are associated with increased mortality.
Prospective cohort studies of 2633 participants from the FHS (Framingham Heart Study; computed tomographic [CT] scans obtained September 2008-March 2011), 5320 from the AGES-Reykjavik Study (Age Gene/Environment Susceptibility; recruited January 2002-February 2006), 2068 from the COPDGene Study (Chronic Obstructive Pulmonary Disease; recruited November 2007-April 2010), and 1670 from ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints; between December 2005-December 2006).
Interstitial lung abnormality status as determined by chest CT evaluation.
All-cause mortality over an approximate 3- to 9-year median follow-up time. Cause-of-death information was also examined in the AGES-Reykjavik cohort.
Interstitial lung abnormalities were present in 177 (7%) of the 2633 participants from FHS, 378 (7%) of 5320 from AGES-Reykjavik, 156 (8%) of 2068 from COPDGene, and in 157 (9%) of 1670 from ECLIPSE. Over median follow-up times of approximately 3 to 9 years, there were more deaths (and a greater absolute rate of mortality) among participants with interstitial lung abnormalities when compared with those who did not have interstitial lung abnormalities in the following cohorts: 7% vs 1% in FHS (6% difference [95% CI, 2% to 10%]), 56% vs 33% in AGES-Reykjavik (23% difference [95% CI, 18% to 28%]), and 11% vs 5% in ECLIPSE (6% difference [95% CI, 1% to 11%]). After adjustment for covariates, interstitial lung abnormalities were associated with a higher risk of death in the FHS (hazard ratio [HR], 2.7 [95% CI, 1.1 to 6.5]; P?=?.03), AGES-Reykjavik (HR, 1.3 [95% CI, 1.2 to 1.4]; P?
Notes
Cites: Am J Respir Crit Care Med. 2015 Feb 15;191(4):417-2625389906
Cites: Am J Respir Crit Care Med. 2001 Sep 15;164(6):1025-3211587991
Cites: Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-30411790668
Cites: N Engl J Med. 2004 Mar 4;350(10):1005-1214999112
Cites: J Am Coll Cardiol. 1990 Mar 15;15(4):827-322407762
Cites: Am J Med. 1990 Apr;88(4):396-4042183601
Cites: Am J Respir Crit Care Med. 1994 Sep;150(3):670-58087336
Cites: Am J Respir Crit Care Med. 1994 Oct;150(4):967-727921471
Cites: Am J Public Health Nations Health. 1951 Mar;41(3):279-8114819398
Cites: Am J Respir Crit Care Med. 2006 Oct 1;174(7):810-616809633
Cites: Am J Epidemiol. 2007 May 1;165(9):1076-8717351290
Cites: Eur Respir J. 2008 Apr;31(4):869-7318216052
Cites: Radiology. 2009 May;251(2):566-7319401580
Cites: Am J Respir Crit Care Med. 2009 Sep 1;180(5):407-1419542480
Cites: Acad Radiol. 2010 Jan;17(1):48-5319781963
Cites: Chest. 2010 Jan;137(1):129-3719749005
Cites: Eur Respir J. 2010 Mar;35(3):496-50420190329
Cites: COPD. 2010 Feb;7(1):32-4320214461
Cites: Med Image Comput Comput Assist Interv. 2009;12(Pt 2):690-820426172
Cites: N Engl J Med. 2010 Sep 16;363(12):1128-3820843247